Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is expected to show significant growth over the coming years, thanks to its robust commercial progress and pipeline growth, with over 30 active projects and four commercial manufacturing site transfer programs since October 2025. The company has a strong leadership team led by CEO Paul Josephs, who has brought a new level of focus and energy to Lifecore and is driving capacity utilization through de-risked commercial opportunities such as site transfers. With a solid balance sheet and expected annual free cash flow of over $10 million in 2026, Lifecore is well positioned for future success.

Bears say

Lifecore Biomedical is currently in the crucial "execution" phase of its turnaround effort under the leadership of CEO Paul Josephs, with emphasis on new business wins and expense management. While new business wins and expense reduction have shown significant progress, the recent hire of Amber Shook as Chief of Staff/Head of Business Transformation suggests that the company still has room for improvement in terms of becoming more streamlined and efficient. Additionally, Lifecore's recent news flow has shown potential for growth, but it may still face challenges in optimizing its business processes and procurement practices.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.